Sphingosine-1 phosphate receptor 1 (S1PR1) expression maintains stemness of acute myeloid leukemia stem cells.

Acute myeloid leukemia Leukemia stem cells S1PR1

Journal

Cancer letters
ISSN: 1872-7980
Titre abrégé: Cancer Lett
Pays: Ireland
ID NLM: 7600053

Informations de publication

Date de publication:
05 Aug 2024
Historique:
received: 16 04 2024
revised: 24 07 2024
accepted: 02 08 2024
medline: 8 8 2024
pubmed: 8 8 2024
entrez: 7 8 2024
Statut: aheadofprint

Résumé

Acute myeloid leukemia (AML) arises from leukemia stem cells (LSCs) and is maintained by cells which have acquired features of stemness. We compared transcription profiles of AML cells with/without stem cell features defined as in vitro clonogenicity and serial engraftment in immune-deficient mice xenograft model. We used multi-parameter flow cytometry (MPFC) to separate CD34

Identifiants

pubmed: 39111385
pii: S0304-3835(24)00553-6
doi: 10.1016/j.canlet.2024.217158
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

217158

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of Competing Interest ☐ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. ☒ The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Robert Peter Gale reports a relationship with Antengene Biotech Limited Liability Company that includes: consulting or advisory. Robert Peter Gale reports a relationship with FFF Enterprises Inc that includes: board membership. Robert Peter Gale reports a relationship with Janssen Pharma and Hengrui Pharma that includes: speaking and lecture fees. Robert Peter Gale reports a relationship with Russian Foundation for Cancer Research Support and Scientific Advisory Board, StemRad Ltd that includes: board membership. Xiaojun Huang has patent #202310435300.1 pending to Peking University People’s Hospital. Xiaojun Huang has patent #202311626667.8 pending to Peking University People’s Hospital. No If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Yu-Qing Wang (YQ)

Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematological Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China; Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China.

Yue Ren (Y)

Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematological Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.

Robert Peter Gale (RP)

Centre for Hematology Research, Department of Immunology and Inflammation, Imperial College London, London, UK.

Li-Ting Niu (LT)

Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematological Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.

Xiao-Jun Huang (XJ)

Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematological Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China; Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China. Electronic address: huangxiaojun@bjmu.edu.cn.

Classifications MeSH